Last reviewed · How we verify
Amphinex, Gemcitabine and Cisplatin
At a glance
| Generic name | Amphinex, Gemcitabine and Cisplatin |
|---|---|
| Also known as | Gemzar (Gemcitabine), Fimaporfin (Amphinex), Cisplatin |
| Sponsor | PCI Biotech AS |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer (PHASE2)
- A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amphinex, Gemcitabine and Cisplatin CI brief — competitive landscape report
- Amphinex, Gemcitabine and Cisplatin updates RSS · CI watch RSS
- PCI Biotech AS portfolio CI